Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel Free IRON Stock Alerts

Disc Medicine (IRON) Competitors

Disc Medicine logo
$56.66 -3.82 (-6.31%)
Closing price 03:59 PM Eastern
Extended Trading
$56.54 -0.12 (-0.21%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

IRON vs. PTGX, KYMR, ARWR, APGE, and TGTX

Should you buy Disc Medicine stock or one of its competitors? Disc Medicine's main competitors and comparable companies include Protagonist Therapeutics (PTGX), Kymera Therapeutics (KYMR), Arrowhead Pharmaceuticals (ARWR), Apogee Therapeutics (APGE), and TG Therapeutics (TGTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Disc Medicine compare to Protagonist Therapeutics?

Disc Medicine (NASDAQ:IRON) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Protagonist Therapeutics has a net margin of 29.40% compared to Disc Medicine's net margin of 0.00%. Protagonist Therapeutics' return on equity of 12.03% beat Disc Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Disc MedicineN/A -37.17% -33.65%
Protagonist Therapeutics 29.40%12.03%11.23%

Protagonist Therapeutics has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Disc MedicineN/AN/A-$212.18M-$6.58N/A
Protagonist Therapeutics$46.02M203.72-$130.15M$1.03140.66

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Disc Medicine currently has a consensus price target of $110.18, indicating a potential upside of 82.18%. Protagonist Therapeutics has a consensus price target of $154.44, indicating a potential upside of 6.60%. Given Disc Medicine's higher probable upside, equities research analysts plainly believe Disc Medicine is more favorable than Protagonist Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Disc Medicine
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77
Protagonist Therapeutics
0 Sell rating(s)
1 Hold rating(s)
17 Buy rating(s)
0 Strong Buy rating(s)
2.94

Disc Medicine has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market.

In the previous week, Protagonist Therapeutics had 9 more articles in the media than Disc Medicine. MarketBeat recorded 10 mentions for Protagonist Therapeutics and 1 mentions for Disc Medicine. Disc Medicine's average media sentiment score of 0.61 beat Protagonist Therapeutics' score of 0.15 indicating that Disc Medicine is being referred to more favorably in the media.

Company Overall Sentiment
Disc Medicine Positive
Protagonist Therapeutics Neutral

Summary

Protagonist Therapeutics beats Disc Medicine on 13 of the 15 factors compared between the two stocks.

How does Disc Medicine compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Disc Medicine (NASDAQ:IRON) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

Disc Medicine has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kymera Therapeutics$39.21M237.68-$311.35M-$3.24N/A
Disc MedicineN/AN/A-$212.18M-$6.58N/A

In the previous week, Kymera Therapeutics had 7 more articles in the media than Disc Medicine. MarketBeat recorded 8 mentions for Kymera Therapeutics and 1 mentions for Disc Medicine. Disc Medicine's average media sentiment score of 0.61 beat Kymera Therapeutics' score of 0.61 indicating that Disc Medicine is being referred to more favorably in the news media.

Company Overall Sentiment
Kymera Therapeutics Positive
Disc Medicine Positive

83.7% of Disc Medicine shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by company insiders. Comparatively, 3.8% of Disc Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Kymera Therapeutics has a beta of 1.98, meaning that its stock price is 98% more volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market.

Disc Medicine has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.22% beat Disc Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Kymera Therapeutics-285.33% -21.22% -19.21%
Disc Medicine N/A -37.17%-33.65%

Kymera Therapeutics currently has a consensus target price of $134.68, suggesting a potential upside of 20.16%. Disc Medicine has a consensus target price of $110.18, suggesting a potential upside of 82.18%. Given Disc Medicine's higher possible upside, analysts clearly believe Disc Medicine is more favorable than Kymera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kymera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.89
Disc Medicine
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77

Summary

Kymera Therapeutics beats Disc Medicine on 10 of the 16 factors compared between the two stocks.

How does Disc Medicine compare to Arrowhead Pharmaceuticals?

Disc Medicine (NASDAQ:IRON) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

Disc Medicine has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Disc Medicine's return on equity of -37.17% beat Arrowhead Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Disc MedicineN/A -37.17% -33.65%
Arrowhead Pharmaceuticals -47.79%-60.06%-17.37%

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Disc Medicine has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market.

Disc Medicine currently has a consensus price target of $110.18, suggesting a potential upside of 82.18%. Arrowhead Pharmaceuticals has a consensus price target of $98.31, suggesting a potential upside of 61.88%. Given Disc Medicine's stronger consensus rating and higher probable upside, equities research analysts clearly believe Disc Medicine is more favorable than Arrowhead Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Disc Medicine
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77
Arrowhead Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.64

Arrowhead Pharmaceuticals has higher revenue and earnings than Disc Medicine. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Disc MedicineN/AN/A-$212.18M-$6.58N/A
Arrowhead Pharmaceuticals$669.50M12.78-$1.63M-$2.25N/A

In the previous week, Arrowhead Pharmaceuticals had 8 more articles in the media than Disc Medicine. MarketBeat recorded 9 mentions for Arrowhead Pharmaceuticals and 1 mentions for Disc Medicine. Disc Medicine's average media sentiment score of 0.61 beat Arrowhead Pharmaceuticals' score of 0.23 indicating that Disc Medicine is being referred to more favorably in the media.

Company Overall Sentiment
Disc Medicine Positive
Arrowhead Pharmaceuticals Neutral

Summary

Disc Medicine beats Arrowhead Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Disc Medicine compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Disc Medicine (NASDAQ:IRON) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

In the previous week, Disc Medicine had 1 more articles in the media than Apogee Therapeutics. MarketBeat recorded 1 mentions for Disc Medicine and 0 mentions for Apogee Therapeutics. Disc Medicine's average media sentiment score of 0.61 beat Apogee Therapeutics' score of 0.00 indicating that Disc Medicine is being referred to more favorably in the news media.

Company Overall Sentiment
Apogee Therapeutics Neutral
Disc Medicine Positive

Apogee Therapeutics has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 83.7% of Disc Medicine shares are owned by institutional investors. 24.3% of Apogee Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Disc Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Apogee Therapeutics currently has a consensus price target of $126.77, indicating a potential downside of 6.14%. Disc Medicine has a consensus price target of $110.18, indicating a potential upside of 82.18%. Given Disc Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Disc Medicine is more favorable than Apogee Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apogee Therapeutics
1 Sell rating(s)
15 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.16
Disc Medicine
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77

Apogee Therapeutics is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apogee TherapeuticsN/AN/A-$255.84M-$4.34N/A
Disc MedicineN/AN/A-$212.18M-$6.58N/A

Apogee Therapeutics' return on equity of -29.88% beat Disc Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Apogee TherapeuticsN/A -29.88% -28.08%
Disc Medicine N/A -37.17%-33.65%

Summary

Disc Medicine beats Apogee Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Disc Medicine compare to TG Therapeutics?

Disc Medicine (NASDAQ:IRON) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

Disc Medicine currently has a consensus target price of $110.18, indicating a potential upside of 82.18%. TG Therapeutics has a consensus target price of $63.00, indicating a potential upside of 13.99%. Given Disc Medicine's stronger consensus rating and higher probable upside, equities research analysts clearly believe Disc Medicine is more favorable than TG Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Disc Medicine
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77
TG Therapeutics
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56

Disc Medicine has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market.

83.7% of Disc Medicine shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 3.8% of Disc Medicine shares are held by company insiders. Comparatively, 8.9% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, TG Therapeutics had 10 more articles in the media than Disc Medicine. MarketBeat recorded 11 mentions for TG Therapeutics and 1 mentions for Disc Medicine. TG Therapeutics' average media sentiment score of 0.65 beat Disc Medicine's score of 0.61 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Disc Medicine Positive
TG Therapeutics Positive

TG Therapeutics has a net margin of 55.22% compared to Disc Medicine's net margin of 0.00%. TG Therapeutics' return on equity of 73.49% beat Disc Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Disc MedicineN/A -37.17% -33.65%
TG Therapeutics 55.22%73.49%34.14%

TG Therapeutics has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Disc MedicineN/AN/A-$212.18M-$6.58N/A
TG Therapeutics$616.29M13.73$447.18M$2.7420.17

Summary

TG Therapeutics beats Disc Medicine on 11 of the 15 factors compared between the two stocks.

Get Disc Medicine News Delivered to You Automatically

Sign up to receive the latest news and ratings for IRON and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IRON vs. The Competition

Export
MetricDisc MedicineBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.19B$3.83B$7.16B$13.16B
Dividend YieldN/A3.65%2.52%20.73%
P/E Ratio-8.6713.31275.8225.79
Price / SalesN/A1,179.23617.86101.74
Price / CashN/A39.4627.3036.12
Price / Book2.9216.9610.706.03
Net Income-$212.18M-$22.69M$3.50B$380.34M
7 Day Performance-7.57%-4.46%-2.90%-2.88%
1 Month Performance-18.66%-11.85%-6.35%-5.05%
1 Year Performance-20.81%9.68%4.16%-2.39%

Disc Medicine Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IRON
Disc Medicine
2.5838 of 5 stars		$56.66
-6.3%		$110.18
+94.5%		-13.5%$2.18BN/AN/A165
PTGX
Protagonist Therapeutics
1.8415 of 5 stars		$138.69
-1.4%		$147.13
+6.1%		+66.5%$8.97B$281.99M134.65141
KYMR
Kymera Therapeutics
2.719 of 5 stars		$105.98
-3.5%		$134.46
+26.9%		+95.9%$8.81B$105MN/A273
ARWR
Arrowhead Pharmaceuticals
2.5049 of 5 stars		$61.54
-1.3%		$98.31
+59.7%		+71.5%$8.67B$829.45MN/A711
APGE
Apogee Therapeutics
0.8043 of 5 stars		$135.07
flat		$126.77
-6.1%		N/A$8.40BN/AN/A91

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:IRON) was last updated on 10/13/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel